2024
The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis
S. D, Kleine N, Teopiz K, Di Vincenzo J, Ho R, Galibert S, Samra A, Zilm S, H. R, d’Andrea G, Gill H, Ceban F, Meshkat S, Wong S, Le G, Kwan A, Rosenblat J, Rhee T, Mansur R, McIntyre R. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis. Expert Opinion On Pharmacotherapy 2024, 25: 5-14. PMID: 38164653, DOI: 10.1080/14656566.2023.2298340.Peer-Reviewed Original ResearchMajor depressive disorderPostpartum depressionDepressive disorderDrug Enforcement AgencyAvailable antidepressant medicationsAvailable clinical studiesTreatment of adultsPositive allosteric modulatorsOral antidepressantsAntidepressant medicationAntidepressant treatmentCommon complicationNeuroactive steroidsSignificant safety concernsClinical trialsEfficacy dataZuranoloneClinical studiesIndirect comparisonMental illnessAllosteric modulatorsMental healthAntidepressantsSafety concernsWomen
2023
Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
Meshkat S, Teopiz K, Di Vincenzo J, Bailey J, Rosenblat J, Ho R, Rhee T, Ceban F, Kwan A, Cao B, McIntyre R. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder. Journal Of Affective Disorders 2023, 340: 893-898. PMID: 37557991, DOI: 10.1016/j.jad.2023.08.027.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntidepressant effectsGamma-aminobutyric acidDepressive disorderAdverse eventsTreatment-emergent adverse eventsFuture research vistasSerious adverse eventsGABAA receptor expressionEtiology of MDDExtrasynaptic GABAA receptorsCommon mental disordersPositive allosteric modulatorsNeuroactive steroidsClinical efficacyTreatment courseInhibitory GABAergicClinical trialsPostpartum depressionZuranoloneGABAA receptorsReceptor expressionTreatment approachesMental disordersAllosteric modulators
2021
Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders
Hecking J, Davoudian PA, Wilkinson ST. Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders. Chronic Stress 2021, 5: 24705470211020446. PMID: 34124495, PMCID: PMC8175843, DOI: 10.1177/24705470211020446.Peer-Reviewed Original ResearchMood disordersMonoamine hypothesisPhase III clinical trialsAmino acid neurotransmitter systemsClassical monoamine hypothesisAmino acid neurotransmittersPublic health issueClinical trialsNovel therapiesNeurotransmitter systemsAV-101Clinical treatmentClinical researchHealth issuesDisordersPotential targetPhase IIPharmaceutical pipelineDrugsGanaxoloneZuranoloneEsketamineBrexanoloneRapastinelPathophysiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply